Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care by Love, M. et al.
antibiotics
Review
Potential for Bacteriophage Endolysins to
Supplement or Replace Antibiotics in Food
Production and Clinical Care
Michael J. Love 1, Dinesh Bhandari 1,2, Renwick C. J. Dobson 1,3 and Craig Billington 1,2,* ID
1 Biomolecular Interaction Centre and School of Biological Sciences, University of Canterbury,
Christchurch 8041, New Zealand; michael.love@pg.canterbury.ac.nz (M.J.L.);
dinesh.bhandari@esr.cri.nz (D.B.); renwick.dobson@canterbury.ac.nz (R.C.J.D.)
2 Institute of Environmental Science and Research, Christchurch 8041, New Zealand
3 Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne 3052, Australia
* Correspondence: craig.billington@esr.cri.nz; Tel.: +64-3-351-0128
Received: 21 December 2017; Accepted: 23 February 2018; Published: 27 February 2018
Abstract: There is growing concern about the emergence of bacterial strains showing resistance to
all classes of antibiotics commonly used in human medicine. Despite the broad range of available
antibiotics, bacterial resistance has been identified for every antimicrobial drug developed to date.
Alarmingly, there is also an increasing prevalence of multidrug-resistant bacterial strains, rendering
some patients effectively untreatable. Therefore, there is an urgent need to develop alternatives
to conventional antibiotics for use in the treatment of both humans and food-producing animals.
Bacteriophage-encoded lytic enzymes (endolysins), which degrade the cell wall of the bacterial
host to release progeny virions, are potential alternatives to antibiotics. Preliminary studies show
that endolysins can disrupt the cell wall when applied exogenously, though this has so far proven
more effective in Gram-positive bacteria compared with Gram-negative bacteria. Their potential
for development is furthered by the prospect of bioengineering, and aided by the modular domain
structure of many endolysins, which separates the binding and catalytic activities into distinct
subunits. These subunits can be rearranged to create novel, chimeric enzymes with optimized
functionality. Furthermore, there is evidence that the development of resistance to these enzymes
may be more difficult compared with conventional antibiotics due to their targeting of highly
conserved bonds.
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1. Introduction
In 2014, the World Health Organization (WHO) calculated the global prevalence of seven
antibiotic-resistant bacteria of international concern, and noted very high rates of resistance (up to
84% of all isolates for methicillin, 81% for third-generation cephalosporins, 49% for fluoroquinolones,
and 60% for penicillin) in all WHO regions [1]. In response to this unprecedented crisis, in late 2016
the United Nations General Assembly called upon the WHO, the Food and Agriculture Organization
of the United Nations, and the World Organisation for Animal Health to develop a global development
and stewardship framework [2]. This request recognized that there was a need to co-ordinate action
against antimicrobial resistance in humans, agriculture, animals, and the environment by using a One
Health [3] approach. One of the key recommendations in the draft framework was to develop new
antimicrobial agents for use in these key sectors.
Here, we discuss the potential of cell wall lysis proteins (endolysins) derived from bacteriophages
for use as a new class of antimicrobial agents, and evaluate whether they could replace, or supplement,
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some of the conventional antibiotics used to treat animals and humans, and perhaps even find use in
food production and environmental decontamination processes.
Endolysins are enzymes encoded by bacteriophages (phage; obligate viruses of bacteria) which
lyse the host bacterial cell. Endolysins degrade the main structural component of the cell wall
(peptidoglycan) at the conclusion of the replicative cycle to release newly assembled progeny phage [4]
(Figure 1). Recombinantly expressed endolysins display similarly effective lytic abilities to their
native counterparts when applied exogenously to susceptible bacteria [5]. This feature underpins the
application of endolysins in medicine, food and agriculture.
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Figure 1. Life cycle of a virulent tailed phage (not to scale). (1) The phage collides with the bacterial cell;
(2) the phage binds to cell receptors; (3) the phage is irreversibly bound and injects nucleic acid into the
cell via the tail tube, where it is transcribed and translated; (4) many progeny phages are produced
within intact cells; (5) endolysins degrade the host bacterial cell wall, which loses its structural integrity
and ruptures due to the osmotic pressure, releasing the progeny phages.
Endolysins are predominantly more effective against Gram-positive bacteria than Gram-negative
bacteria when applied in this way. The outer membrane of Gram-negative bacteria presents a physical
protective barrier against the activity of endolysins [6]. Therefore, endolysin research has mainly
focused on Gram-positive bacteria. However, recent work on outer membrane permeabilizers
(chemicals and engineered peptides) should increase the prospects of endolysins for treating
Gram-negative bacteria.
Numerous types of endolysins have been described, and are typically categorized by the structural
bonds in the peptidoglycan that are cleaved by the enzyme [7] (Figure 2). The two alternating glycosidic
bonds between the amino sugar moieties, N-acetylglucosamine and N-acetylmuramic acid (MurNAc),
are targeted by different endolysin classes. The N-acetylmuramoyl-β-1,4-N-acetylglucosamine
bond is cleaved by lytic transglycosylases and N-acetyl-β-D-muramidases, which are commonly
known as lysozymes, while the N-acetylglucosaminyl-β-1,4-N-acetylmuramine bond is hydrolysed
by N-acetyl-glucosaminyl-β-D-glucosaminidases. The cleavage of the amide linkage between
MurNAc and L-alanine is catalyzed by N-acetylmuramoyl-L-alanine amidases. There are different
endopeptidases depending on the chemical structure of the peptidoglycan, which is dependent on
species and growth conditions. Generally, endopeptidases hydrolyze the peptide bonds between the
amino acids that form the cross-linking peptide stems [8–10].
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Figure 2. Diagram of the typical cell wall and peptidoglycan structure of bacteria, including the
endolysin cleavage sites. The peptidoglycan is composed of repeating sugar units, N-acetylglucosamine
(GlcNAc) and N-acetylmuramic acid (MurNAc), which are cross-linked via an interpeptide
bridge between the meso-diaminopimelic acid (m-DAP) and D-alanine (D-Ala) residues of adjacent
tetrapeptide chains. The chains also contain L-alanine (L-Ala) and D-glutamic acid (D-Glu).
Gram-negative bacteria contain an outer membrane (OM) structure not present in Gram-positive
bacteria. Both contain an inner membrane (IM) structure. The cleaved bonds and major classifications
of endolysin are indicated: (1) N-acetylmuramoyl-L-alanine amidase; (2–4) various endopeptidases;
(5) N-acetyl-β-D-glucosaminidase; (6) N-acetyl-β-D-muramidase (lysozyme).
A number of promising endolysins have been isolated from phage for application as antimicrobial
agents, as described in this review and others [5–9]. However, the bioengineering of modified or
novel endolysins also holds promise for the future development of effective tools to kill or detect
bacteria. The prospects for engineering are facilitated by the enzymes’ structures. The domain
structure of endolysins can be modular (Gram-positive bacteria and some Gram-negative species)
or globular (most Gram-negative bacteria), with most bioengineering strategies exploiting the
modular endolysins. These enzymes usually comprise two distinct domains: an N-terminal
enzymatically-active domain and a C-terminal cell wall-binding domain, connected by short, flexible
linker regions. N-terminal enzymatically-active domains are responsible for catalyzing the breakdown
of specific peptidoglycan bonds, while the C-terminal cell wall-binding domains recognize and bind
non-covalently to substrate within the cell wall, resulting in the specificity of the lytic enzymes for the
target host [5,8]. In addition, the C-terminal cell wall-binding domain is often required to maintain full
lytic activity [11–13]. Interestingly, truncation or deletion of the C-terminal cell wall-binding do ain
can also result in equal or increased lytic activity [14–16]. In contrast, globular endolysins only contain
catalytic domains.
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The modular endolysin arrangement can be exploited for bioengineering, as the different domains
can be shuffled within the protein, or domains from different endolysins can be combined to generate
new enzymes [17,18]. Directed mutagenesis is also an effective strategy, as different amino acids may
support improved lytic or binding properties [5,8,17,18]. The seemingly limitless possible permutations
of endolysin modular arrangements allow for the development of new enzymes with specific functions
or features. Some potential bioengineering strategies and examples of endolysin constructs are shown
in Table 1.
Table 1. Possible molecular engineering strategies with potential application(s).




and solubility CHAPk Horgan et al. [19]
Fusion of EADs with CBDs of
different endolysins
Increased catalytic ability
and solubility ClyS Daniel et al. [20]
Increased catalytic ability and
broader lytic spectrum
SA2-E-Lyso-SH3b,
SA2-E-LysK-SH3b Schmelcher et al. [21]
Thermostability PlyGVE2CpCWB Swift et al. [22]
Fusion of virion-associated lysin
with CBD of endolysin Increased efficacy EC300 Proença et al. [23]
Endolysin fusion with OMP Increased efficacy towardsGram-negative bacteria
OBPgp279,
PVP-SE1g-146 Briers et al. [24]
Endolysin fusion with AMP Increased efficacy towardsGram-negative bacteria Art-175 Briers et al. [25]
Truncation and
site-directed mutagenesis AMP development LysAB2 Peng et al. [26]
EAD: enzymatically-active domain; CBD: cell wall-binding domain; OMP: outer-membrane permeabilizer; AMP:
antimicrobial peptide.
Both bioengineered and phage-isolated endolysins are promising alternatives to antibiotics.
Their specificity allows them to target specific bacterial pathogens without affecting the microflora [11],
or alternatively, target a larger spectrum for broader efficacy [27]. At the moment, developed resistance
to the activity of the endolysins has not been widely reported, meaning these enzymes could be a
long-term solution to antibiotics [28–30]. Endolysins may also have potential as diagnostic tools for
bacterial identification [31]. In the following sections, we provide an overview of native and chimeric
endolysins with potential therapeutic applications.
2. Endolysins as Human Therapeutics
As the efficacy of antibiotics decreases, once easily-treated bacterial infections will become
potentially fatal. This will also have secondary effects in clinical care, such as changing risk-benefit
considerations for invasive surgeries. Phage-encoded lytic enzymes have the potential to fulfil
the need for novel antibacterial therapeutic agents for use in humans. This new class of
antimicrobials has been recognized by the United States of America in the National Action Plan
for Combating Antibiotic-resistant Bacteria [32], which identified the use of “phage-derived lysins to
kill specific bacteria while preserving the microbiota” as a key strategy to reduce the development of
antimicrobial resistance.
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant public health concern, causing a
range of skin and respiratory infections, as well as food-borne illnesses that are not easily treatable with
currently available antibiotics [33]. O’Flaherty et al. [27] treated a human-derived MRSA strain with
Lactococcus lactis cell lysate containing recombinantly overexpressed endolysin LysK, and observed a
99% reduction in colony-forming units at 1 h post-exposure. However, the researchers had difficulties
obtaining soluble protein, which would hinder future applications of LysK, a difficulty that was also
encountered in subsequent studies [34,35]. A stability study was conducted on LysK, as medical
application requires a stable enzyme [34]. LysK was stabilized in the presence of low molecular
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weight polyols such as sucrose and glycerol, for example, stability increased 100-fold at 30 ◦C,
and LysK retained 100% activity after storage up to 1 month at room temperature. This stability,
under simple condition changes, is useful for developing treatment strategies [34]. LysK contains two
catalytic domains: a cysteine- and histidine-dependent amidohydrolase/peptidase (CHAP) domain,
and an N-acetylmuramoyl-L-alanine amidase domain. In an attempt to overcome the solubility issue,
Horgan et al. [19] generated a single-domain truncated LysK mutant, designated CHAPk, containing
only the CHAP domain. Soluble CHAPk was easier to obtain than full-length LysK, and displayed at
least a two-fold increase in lytic activity against both heat-killed and live staphylococcal cells in vitro.
Subsequent studies demonstrated that CHAPk was also effective in vivo, and that the loss of the
C-terminal cell wall-binding domain, which directs specificity, resulted in activity against a broader
range of targets compared with full-length CHAPk [36,37].
Jun et al. [38] compared LysK with SAL-1, an endolysin that differs by three residues. They also
produced six derivatives of SAL-1 containing mutations in each of the three residues to investigate
the impact of each mutation. SAL-1 displayed cell-wall hydrolytic activity approximately two-fold
greater than that of LysK. The mutation of residue 114 from glutamatic acid in LysK to glutamine in
SAL-1 had the largest impact on activity. This residue is located inside the catalytic CHAP domain,
and the structurally minor sequence change corresponded to enhanced activity. The combination of
such enhanced activity with the identification and mechanistic characterization of key residues of
different enzymes is important for rational design and engineering of new endolysins with optimized
activity [38]. Compared with LysK, SAL-1 had increased catalytic activity, and high yields of soluble
protein were easier to obtain; therefore, SAL-1 may be a more promising antibiotic alternative than
LysK [39]. The therapeutic application of SAL-1 is currently being trialed by iNtRON Biotechnology in
the form of SAL200, an endolysin-based candidate drug for the treatment of S. aureus. A preclinical
safety study of SAL200 observed no toxicity in rodent intravenous single- and repeat-dose studies [40].
A repeat-dose experiment was also performed in dogs, with each dog receiving four doses of 0, 0.5,
12.5 and 25 mg/kg in 1-week intervals over four weeks. After ten days, short-lived (i.e., lasting only
30 minutes to 1 hour) and mild clinical signs were observed including, vomiting, subdued behavior
and irregular respiration. The transient response of the dogs to SAL200 administration was linked
to complement system activation that resulted from antibody production [40]. A follow-up study in
monkeys investigated the impact of single-dose escalation (up to 80 mg/kg) or 5-day multiple-dose
(up to 40 mg/kg/day) administration of SAL200, with no adverse effects observed [41] SAL200 was
further evaluated in a human single dose-escalating (up to 10 mg/kg) study. This study was the first
in-human clinical study of a intravenously administered endolysin-based drug [42]. The volunteers
had a reasonable tolerability to SAL200, with no significant adverse effects and most of the adverse
effects were mild and self-limited. Although an increased concentration of antibodies was observed,
the antibody concentration of participants administered 3.0 mg/kg was greater than that of those
administered 10 mg/kg, with large variation within the different cohorts. The immunogenicity of
SAL200 should, therefore, be a focus of future studies in order to better develop treatment regimes [42].
A phase II clinical study is now being conducted on patients with persistent S. aureus bacteremia, with
results expected in 2018. Overall, the current evaluations shows a promising future for not just SAL200,
but also for the development of other endolysin-based drug treatments.
Biofilm formation in clinical environments and on medical devices can have significant medical
implications, as biofilms can harbor pathogenic and multidrug-resistant bacteria. Microorganisms
within biofilms are protected by extracellular polymeric substances (EPS), which are a source of
environmental contamination when partially dislodged. EPS can contain polysaccharides, proteins,
phospholipids, teichoic acids, nucleic acids, and polymers, and protect the biofilm inhabitants by
concentrating nutrients, preventing access of biocides, sequestering metals and toxins, and preventing
desiccation [43]. Linden et al. [44] found that recombinantly-expressed PlyGRCS (from the phage
GRCS) effectively lysed S. aureus in a biofilm, as well as in stationary phase. PlyGRCS contains a single
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enzymatically-active domain that can cleave two different bonds in peptidoglycan. This bifunctional
domain could be highly useful in developing endolysins with effective lytic activity.
Rashel et al. [45] found that a dose of the phage φMR11-derived lysin MV-L rescued mice
from fatal levels of MRSA exposure. In addition, MV-L in combination with vancomycin killed
vancomycin-resistant strains. MV-L was specific for S. aureus and Staphylococcus simulans, with no lytic
activity observed against other staphylococcal strains or bacterial species, including Staphylococcus
epidermidis and Escherichia coli. Although excessive exposure to MV-L induced the production of
antibodies, no adverse effects on the mice or impact on the efficacy of MV-L was observed.
Daniel et al. [20] demonstrated the potential of bioengineering to generate enzymes with novel and
specific lytic activity against MRSA. The endolysin ClyS was constructed from the enzymatically active
domain of a S. aureus Twort phage lysin fused with the cell wall-binding domain of phiNM3. Mice were
exposed to MRSA strains that were resistant to the antibiotic oxacillin. A dose of ClyS increased survival
rates to 88%, compared with the 0% survival rate for untreated mice. Treatment of infected mice
with a sub-therapeutic concentration of ClyS in combination with oxacillin increased survival rates
when compared with each treatment alone. This synergistic relationship with antibiotics may have
widespread potential, and reinitiate the use of historical antibiotics that have been discontinued due to
resistance concerns.
Schuch et al. [46] further showed this synergistic potential with the lysin CF-301. Mice with
staphylococcal-induced bacteremia had a survival time of less than 24 h without treatment.
Following individual treatments with CF-301 and daptomycin at 4 h post-inoculation, survival rates
after 72 h were measured at 13% and 23%, respectively. Combination therapy yielded a survival rate of
73%. The study further confirmed the efficacy of co-therapy in 16 individual experiments including the
antibiotics oxacillin and vancomycin. The immunogenicity of CF-301 was briefly evaluated in vitro;
rabbit antisera raised against CF-301 did not inhibit the activity of CF-301 [46]. Despite the in vitro
results, the immunogenic nature of CF-301 needs to be studied in a range of model organisms in vivo,
because there may be clinically relevant adverse effects. CF-301 also has anti-biofilm activity [47],
and clinical phase I trials are now underway to evaluate CF-301 as an alternative to traditional
antibiotics, with an expected study completion in late 2018.
Thermal injury patients are usually also immunocompromised, meaning they are more susceptible
to bacterial infection, including drug-resistant S. aureus strains [48]. Chopra et al. [49] investigated the
use of endolysin MR-10 alone and in combination with minocycline to treat burn wound infections
in mice. The control mice, inoculated with S. aureus and receiving no medical treatment, had a 100%
mortality rate within 5 days. Individually, MR-10 (50 µg/ml) and minocycline (50 mg/kg) both
resulted in a survival rate of 35% at 5 days post-inoculation, but 100% mortality was observed by day
7. In contrast, 100% survival was observed following treatment with a combination of the therapeutic
agents at the same concentrations. These findings further support the future use of endolysins in
medicine, especially in co-therapy with existing antibiotics.
Staphefekt is an endolysin bioengineered to selectively target S. aureus strains, including MRSA.
It is currently available as a component of gels and creams for over-the-counter treatment of
infections [50,51]. Its specificity for S. aureus is an important feature in the treatment of skin infections,
as it prevents the disturbance of commensal bacteria, which can cause further health complications [52].
Evidence for the efficacy of Staphefekt is limited; there are few available publications describing the
rationale of engineering or the in vitro properties and structure of the endolysin. However, a recent
report by Totté et al. [51] demonstrated the efficacy of Staphefekt in treating three different patients
with recurrent S. aureus-related dermatoses that had previously been unsuccessfully treated with
antibiotics. Despite the limited published evidence, these brief findings suggest a promising future for
Staphefekt as a long-term alternative to antibiotics.
Enterococcus faecalis is the third most common cause of life-threatening nosocomial infections [53],
and is intrinsically resistant to antibiotics [54]. Although vancomycin is considered a drug of last
resort, a growing number of vancomycin-resistant E. faecalis strains have been isolated. [55,56].
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An endolysin isolated from phage φ1, PlyV12, kills a variety of E. faecalis strains in vitro, including
vancomycin-resistant isolates. PlyV12 also showed a broad spectrum of lethality against a variety
of streptococcal and staphylococcal strains, highlighting it as a promising candidate in antibacterial
medicine [57]. Son et al. [58] also identified a novel phage, EFAP-1, which was not significantly
similar to any previously identified phages. The endolysin of EFAP-1, EFAL-1, exhibited lytic activity
against 24 different strains of bacteria, including vancomycin-resistant E. faecalis strains and four
streptococcal strains, whereas the phage itself only showed activity against E. faecalis. There is a lack
of in vivo studies of E. faecalis endolysins. Such studies are important because E. faecalis is also a
commensal bacterium found in the human gut, and therefore the potential impact of endolysins on the
gut microbiota needs to be understood [52]. Zhang et al. [59] isolated phage IME-EF1 and its endolysin
from hospital sewage, and investigated their ability to rescue mice from lethal challenge with E. faecalis.
Individually, both the phage and the endolysin reduced the bacterial count in the blood of infected
animals. However, a 200-µg dose of the endolysin at 30 min post-bacterial inoculation supported a
higher survival rate (80%) than that observed following phage treatment alone (60%) [59].
The endolysin LysEF-P10, derived from E. faecalis phage EF-P10, has also been studied in a mouse
model. A single dose of just 5 µg was enough to protect mice from vancomycin-resistant E. faecalis
infection, suggesting promising protective efficacy of LysEF-P10 against vancomycin-resistant E. faecalis
strains. Furthermore, when the mice were subjected to a large dose of 5 mg, no side effects were
observed. The administration of EF-P10 stimulated specific antibody production, however, there
was no impact on the bactericidal activity of the enzyme. Treatment with EF-P10 did not negatively
affect the gut microbiota, owing to the specificity of the lysin. Although E. faecalis in the normal
gut microbiota may have been targeted, no significant health impact on the mice was observed [60].
Proença et al. [23] constructed a bacteriolysin-like enzyme to target E. faecalis. The construct, EC300, was
created from the fusion of the peptidase domain from a virion-associated lysin and the cell wall-binding
domain of Lys170, both found in phage F170/08. EC300 inhibited the growth of E. faecalis in bacterial
culture media, whereas the parental endolysin Lys170 showed limited inhibition. The enhanced
lytic and killing ability of EC300 highlights the potential for engineered endolysins compared with
wild-type enzymes.
Streptococcal infections are associated with a range of clinical manifestations, including strep
throat, pneumonia, skin infections, and meningitis [61,62]. Drug resistant streptococcal strains are
also increasing in prevalence. Loeffler et al. [28] examined the potential of the endolysin Pal to kill
S. pneumoniae that had colonized the nasopharynx of mice. Pal was effective against 15 different
strains of pneumococci, including some drug-resistant strains, reducing S. pneumoniae to undetectable
levels within 5 h of treatment. The same research group [63] then examined the antibacterial ability
of a previously described lytic enzyme, Cpl-1 [64]. Rabbit antiserum was raised against Cpl-1 and
the impact on bacterial lysis measured. Only a small amount of inhibition was measured, showing
the antibodies had little effect on the enzymatic activity [63]. In the same study, these findings were
corroborated in vivo. Mice that were subjected to several doses of Cpl-1 tested positive for IgG.
These immunized mice along with naïve mice were challenged with S. pneumoniae. Comparatively,
no significant difference was measured with regards to the reduction of bacteria numbers by the
enzyme [64]. Mice intravenously infected with S. pneumoniae and treated only with buffer had a
median survival time of 30.75 h, with no mice surviving at 72 h post-infection. Mice treated with Cpl-1
at 5 and 10 h post-infection had a median survival time of 60 h, although after 96 h, only one mouse
survived. Although the potential for complete eradication of the bacteria was shown, the dosage used
in the experiments was not high enough, meaning that all animals eventually succumbed to infection.
Therefore, for greater efficacy of Cpl-1, a higher dose would be required [63].
Subsequent studies demonstrated the effectiveness of Cpl-1 combination therapy with lytic
enzyme Pal, or with antibiotics [65–67]. In vivo mouse model studies demonstrated these
Cpl-1 treatments were effective in the treatment of pneumococcal diseases such as sepsis [68],
endocarditis [69], meningitis [70], and pneumonia [71,72]. Despite its demonstrable antibacterial
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activity, a key limitation of Cpl-1 is its half-life in blood of only 20.5 min in mice [63,69]. Resch et al. [72]
introduced specific cysteine residues into Cpl-1 to promote disulfide bond formation and subsequent
dimerization. Dimerization is required for full activity of LytA, a pneumococcal autolysin [73], with
which Cpl-1 shares extensive sequence similarity. Dimerized Cpl-1 displayed a two-fold increase in
antimicrobial activity and had a nearly ten-fold decrease in plasma clearance, resulting in an increased
half-life. These enhanced properties not only increase the prospects for Cpl-1 application, but also
highlight the potential for enhanced activity through structural changes and engineering.
The exogenous treatment of Gram-negative bacteria with endolysins has been limited because
of the presence of the outer membrane, which prevents access to the peptidoglycan layer [74].
Overcoming this protective layer is a major obstacle in developing endolysin-based treatments.
Most studies have focused on nosocomial pathogens Acinetobacter baumannii and Pseudomonas
aeruginosa, both of which are Gram-negative and capable of forming biofilms. Multidrug-resistant
strains of both pathogens are also being increasingly isolated [75–78]. Some endolysins can
intrinsically permeate the outer membrane [79–81]. Lai et al. [79] recombinantly expressed LysAB2
from φAB2 and applied it to A. baumannii. The C-terminus of LysAB2 contains an amphipathic
α-helix that interacts with the negatively charged elements of the outer membrane, facilitating the
formation of a transmembrane pore [82]. This allows the N-terminus catalytic domain to interact
with the peptidoglycan layer and lyse the cell, achieving antibacterial activity. Lood et al. [80]
identified and screened 21 different endolysins for sequence diversity and A. baumannii-killing activity.
The endolysins displayed varying degrees of antibacterial activity, with the lysin PlyF307 exhibiting
the greatest activity. The C-terminus of PlyF307 contains a highly positively charged region, which
may interact with the outer membrane. PlyF307 successfully killed both planktonic cells and, more
importantly, those within biofilms, providing an advantage over antibiotics. PlyF307 also functioned
under physiological conditions, rescuing mice treated with lethal doses of A. baumannii. There remains
a library of lysins for structural and biochemical characterization from this research.
Walmagh et al. [81] showed that OBPgp279, from the phage OBP, can permeate the outer
membrane of P. aeruginosa. It does not appear to contain an amphipathic helix, and thus the mechanism
of permeabilization is unclear. OBPgp279 may therefore contain novel structural elements that could
lend themselves to the engineering of new endolysins to target Gram-negative bacteria [81]. The lysin
LysPA26 from phage JD010 has antibacterial activity against both planktonic and biofilm-contained
P. aeruginosa cells, as well as other Gram-negative species such as E. coli and Klebsiella pneumoniae.
However, LysPA26 was ineffective against Gram-positive species, including S. aureus. This specificity
may allow for selective targeting of Gram-negative species in medical treatments [83].
Strategies employing endolysins in conjunction with antibiotics or outer
membrane-permeabilizing agents have been explored. Thummeepak et al. [84] investigated
the use of LysABP-01 in combination with colistin for treatment of hospital-isolated strains of
A. baumannii. Although LysABP-01 alone prevented growth, elevated levels of antibacterial activity
were observed in combination with colistin. Additionally, the minimum inhibitory concentrations
of LysABP-01 and colistin were reduced 32-fold and by up to eight-fold, respectively, when used in
combination, compared with individual application. Endolysin EL188, from phage EL, combined with
EDTA reduced P. aeruginosa cell counts by up to four log units, whereas EL188 on its own exhibited
no antibacterial activity [85]. However, the use of EDTA would be restricted to topical applications
because of its ability to inhibit blood coagulation [86].
Artilysin bioengineering has also shown promise in targeting Gram-negative bacteria.
Artilysins are created through the fusion of outer membrane-permeabilizing peptides, which interfere
with the stabilizing forces within the outer membrane, with endolysins. These fusion proteins
allow the uptake of an endolysin across the outer membrane, providing access to the peptidoglycan
layer [87]. Initially, two endolysins, OBPgp279 and PVP-SE1g-146, fused with one of seven different
peptides were investigated for their antibacterial activity. Although the endolysins exhibited limited
antibacterial activity on their own, fusion with polycationic nonapeptide correlated with up to a 2.6 log
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reduction of P. aeruginosa in only 30 min. Moderate antibacterial activity against A. baumannii, E. coli,
and Salmonella Typhimurium was also observed. The mode of action was examined using time-lapse
microscopy, confirming that the artilysins were passing through the outer membrane and degrading
the peptidoglycan [24].
Briers et al. [25] developed Art-175, composed of the antimicrobial peptide (AMP) sheep
myeloid 29-amino acid peptide (SMAP-29) fused with endolysin KZ144, to target P. aeruginosa.
AMPs are involved in the innate immune response, and can move across the outer membrane [88].
Art-175 reduced the P. aeruginosa cell count by up to 4 log units compared with untreated controls,
and continuous exposure to Art-175 to exert a selection pressure did not elicit the development of
resistance. On its own, SMAP-29 is cytotoxic to mammalian cells [89]; however, Art-175 exhibited
little toxicity in L-292 mouse connective tissue. As a result of these findings, Peng et al. [26] developed
AMPs based on the amino acid sequence of LysAB2. The synthesized AMPs killed A. baumannii cells
by permeating the outer membrane in vitro. Treatment with the AMPs also increased the survival rate
of mice infected with a lethal dose of A. baumannii by 60%. This research highlights a novel method of
bioengineering endolysins for use as antimicrobials.
3. Endolysins as Veterinary Treatments
In response to widespread concern regarding the overuse of antibiotics in food-producing animals,
many major food suppliers are now committed to phasing out prophylactic antibiotic use and the
tighter control of therapeutic treatments. This presents obvious challenges for the animal-husbandry
industry, which may be overcome by the use of endolysins. Companion and working animals can
also be susceptible to recalcitrant microbial infections, including those caused by multidrug-resistant
microorganisms, and so may also benefit from endolysin treatment.
Clostridium perfringens is a leading cause of necrotic enteritis and sub-clinical disease in poultry,
and can lead to significant economic losses [90]. Swift et al. [22] constructed recombinant endolysin
PlyGVE2CpCWB, which shows enhanced thermostability, an important feature for surviving feed
heat treatments. The recombinant endolysin contains an amidase domain from an endolysin derived
from a thermophilic phage fused with the cell wall-recognition domain from C. perfringens-specific
phage endolysin PlyCP26F, which is not resistant to high temperatures. PlyGVE2CpCWB inactivated
C. perfringens in both liquid and solid media at temperatures up to 50 ◦C, and so may be a
promising antimicrobial feed treatment for controlling necrotic enteritis in poultry. This thermostable
construct demonstrates the potential for other thermophilic bacteriophage endolysins to be utilized
in bioengineering. A different approach to C. perfringens control was taken by Gervasi et al. [91,92],
whereby an amidase endolysin (CP25L) was cloned and expressed in a Lactobacillus johnsonii strain
isolated from poultry. In co-cultures, reductions of up to 2.6 log10 CFU·ml−1 C. perfringens were noted;
however, the reduction was inconsistent between experiments, and the effect declined significantly
over time. This reduced activity was attributed to a loss in stability of the endolysin in culture,
and a reduction in the viability of L. johnsonii. Other researchers [93,94] have also performed detailed
analyses, including X-ray crystallography, on another C. perfringens endolysin, Psm, which may
have applications in poultry. Psm is an N-acetylmuramidase endolysin with wide activity against
C. perfringens strains.
Another economically significant disease in animal husbandry is bovine mastitis, which is
caused by a variety of bacteria, of which staphylococci and streptococci account for 75% of cases [95].
In studies aimed at treating bovine mastitis caused by S. aureus, Schmelcher et al. [21] demonstrated
that fusion of an endopeptidase endolysin domain from a Streptococcus lambda phage (SA2) with either
lysostaphin (SA2-E-Lyso-SH3b) or staphylococcal phage endolysin LysK (SA2-E-LysK-SH3b) could
inhibit staphylococci in a murine mammary mastitis model. The extended lytic spectrum targeting
multiple genera would be particularly useful for efficiently treating bovine mastitis [96]. Infusion of
25 µg of SA2-E-Lyso-SH3b or SA2-E-LysK-SH3b into the mammary glands reduced S. aureus counts by
0.63 and 0.81 log10 CFU·mg−1, respectively. Additional testing of SA2-E-LysK-SH3b and lysostaphin
Antibiotics 2018, 7, 17 10 of 25
in combination (12.5 µg/gland) revealed a 3.36 log10 CFU·mg−1 reduction in the concentration of
S. aureus compared with the control [21]. Further work by the same group [97], determined the
potential of the lambda SA2 and phage B30 (a CHAP endopeptidase) endolysins in combination as a
therapeutic treatment of Streptococcus-induced mastitis, again in a murine mastitis model. The best
results obtained by the study were reductions of 1.5 log10 CFU·mg−1 against Streptococcus uberis (SA2),
4.6 log10 CFU·mg−1 against Streptococcus agalactiae (B30), and 2.2 log10 CFU·mg−1 against Streptococcus
dysgalactiae (SA2). More recently, purified endolysin Trx-SA1, isolated from S. aureus phage IME-SA1,
was used to treat naturally infected cow udders [98]. Udder quarters received an intramammary
infusion of 20 mg of Trx-SA1 once per day, and qualitative reductions in somatic cell counts and
S. aureus numbers were noted over the three-day regime.
Anthrax, a potentially fatal zoonotic disease affecting a wide variety of species, is a threat to wild
and farmed animals as well as humans, especially as a biological weapon [99,100]. Schuch et al. [29]
reported the usefulness of PlyG lysin, isolated from the γ-phage of Bacillus anthracis, in killing
vegetative cells and germinating spores of B. anthracis and streptomycin-resistant Bacillus cereus RSVF1.
The researchers screened an expression library of cloned γ-phage DNA sequences and identified a
702-bp open reading frame (ORF) encoding a protein with homology to an amidase-type endolysin.
When PlyG was injected intraperitoneally (50 U in 0.5 mL) into mice infected with 6 log10 CFU
RSVF1, a notable therapeutic effect was observed, with 68.4% (13/19) of mice showing full recovery.
Furthermore, the survival time of the remaining mice was prolonged to 21 h post-infection.
Equine strangles is a highly contagious disease of horses caused by Streptococcus equi. The disease
progresses as an inflammation of the upper respiratory tract, and leads to abscess formation in the
retropharyngeal lymph node [101]. Strangles is a significant economic threat to the horse racing
industry, where many high value animals are typically housed in close proximity. Hoopes et al. [102]
used PlyC, an unusual multimeric amidase-type endolysin [17], as a disinfectant against S. equi and
reported it to be 1000 times more active on a per weight basis than the widely used disinfectant
Virkon-S. PlyC was effective against >20 clinical isolates of S. equi, including both S. equi subsp. equi
and S. equi subsp. zooepidemicus, demonstrating its sterilizing ability against an eight log CFU·ml−1
culture of S. equi within 30 min of exposure.
The clinical efficacy of a muramidase as a veterinary treatment for companion animals was
demonstrated in a trial by Junjappa et al. [103], where they successfully treated 17 dogs suffering from
pyoderma (bacterial skin lesions) caused by MRSA. The skin lesions were treated with a hydrogel
containing a chimeric endolysin composed of the cell wall-targeting domain (SH3b) of lysostaphin and
the phage K ORF56 muralytic domain [104]. Another important zoonotic pathogen, Streptococcus suis,
has been linked to arthritis, meningitis, septicemia, and endocarditis in pigs, as well as in humans who
have come into contact with infected animals or their byproducts. Wang et al. [105] isolated a phage
from S. suis (SMP), and then expressed the endolysin LySMP in E. coli BL21. The resultant product,
following chromatography and treatment with β-mercaptoethanol, killing 15 out of 17 clinical S. suis
serotype 2 isolates from diseased pigs in China, and had demonstrated activity against S. suis serotype
7 and 9 strains, S. equi subsp. zooepidemicus, and S. aureus [105].
There is growing evidence to suggest that food-producing animals are an important global
reservoir of vancomycin-resistant enterococci (VRE) [106,107]. This group of potentially invasive
microorganisms is resistant to almost all of the available antibiotic regimens recommended for
treatment of Gram-positive bacterial infections. In an attempt to combat VRE in food-producing
animals, Yoong et al. [57] cloned the PlyV12-encoding gene from enterococcal phage Φ1 into the
E. coli-Bacillus shuttle vector pDG148, followed by its expression in Bacillus megaterium strain WH320.
The resultant product, an amidase-type endolysin, had lytic activity against 14 clinical and laboratory
E. faecalis and Enterococcus faecium strains, including two vancomycin-resistant E. faecalis and three
vancomycin-resistant E. faecium strains, in addition to its host, E. faecalis V12. Intriguingly, PlyV12 also
had a significant killing effect on pathogenic streptococcal strains, including Streptococcus pyogenes
(group A streptococcus) and group C streptococci.
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Diarrheal outbreaks caused by Clostridium difficile have frequently been reported in animals,
including cattle, horses, and pigs [108,109]. Treatment of C. difficile diarrhea with antibiotics is not
recommended as it can further exacerbate the disease condition [110]. In a quest for an alternative
approach to treat infections caused by C. difficile, Mayer et al. [111] sequenced the genome of a
temperate phage from C. difficile. They identified endolysin gene cd27l and cloned it into vectors
pET15b and pUK200 to express the gene product in E. coli and L. lactis, respectively. The purified
endolysin was active against 30 diverse strains of C. difficile, including those belonging to the major
epidemic ribotype, 027 (B1/NAP1). Unlike antibiotics, the endolysin was selective for C. difficile,
demonstrating no activity against a range of commensal species from within the gastrointestinal tract,
including other clostridia, bifidobacteria, and lactobacilli.
Paenibacillus larvae subsp. larvae causes American Foulbrood disease in honey bees, which are
important insect pollinators of agricultural crops. The disease occurs in honeybee larvae as a result
of P. larvae spores germinating in the larval midgut and subsequently causing sepsis and death.
The use of antibiotics to treat the disease in the USA now requires supervision by a veterinarian, and a
withholding period of 4–6 weeks is recommended for honey from treated hives prior to sale (https://
www.fda.gov/AnimalVeterinary/ResourcesforYou/AnimalHealthLiteracy/ucm309134.htm). In the
European Union, no veterinary medicines containing antibiotics are permitted in beekeeping (http:
//europroxima.com/european-legislation-regarding-antibiotics-in-honey-an-overview/). For these
reasons, endolysins are being investigated as a potential alternative control tool. An amidase endolysin,
PlyPl23, has been cloned from a P. larvae phage and subsequently expressed [112]. In bee larvae
experimentally infected with spores, PlyPl23 effectively decreased the rate of P. larvae infection, and no
toxic side effects were noted in the larvae. However, the endolysin was not effective until the spores
had germinated.
4. Endolysins as Food and Environmental Decontaminants
During post-harvest processing, food is vulnerable to cross-contamination from microbial
pathogens, which pose a risk to food safety, as well as from microorganisms that can cause quality or
shelf-life defects. Effective interventions for foods and the food processing environment are therefore
vital to maintain the integrity of the food supply chain. Endolysins have the potential to be key
intervention tools for this purpose.
The use of endolysins to prevent contamination of ready-to-eat foods by the common food
and environmental pathogen Listeria monocytogenes has been established by groups from around
the world [16,113–117]. Zhang et al. [113] cloned an endolysin gene (lysZ5) from the genome of
L. monocytogenes phage FWLLm3 into E. coli and tested the sterilization efficacy of the expressed
protein (a murine hydrolase) in soya milk contaminated with L. monocytogenes. The purified
protein had a bactericidal effect on L. monocytogenes growing in soya milk, with the pathogen
concentration reduced by more than 4 log10 CFU·ml−1 after 3 h of incubation at 4 ◦C. Furthermore,
the protein displayed a broad host spectrum, lysing lawn cultures of L. monocytogenes, Listeria innocua,
and Listeria welshimeri. In a different approach, van Nassau et al. [114] tested the combined effect of
previously characterized endolysins (PlyP40, Ply511, or PlyP825) and high hydrostatic pressure on the
survival of L. monocytogenes. They reported that the combination of treatments had a synergistic effect,
capable of reducing viable cell counts of L. monocytogenes by up to 5.5 log10, compared with 0.3 and
0.2 log10 CFU reductions, respectively, when used alone.
Turner et al. [115] and Gaeng et al. [16] demonstrated that the L. monocytogenes endolysin gene
ply511 can be cloned and expressed in Lactobacillus spp., which have potential as biopreservatives in
foods and as a starter culture for fermented milk products. Further to this, Turner et al. [115] combined
the cloned A511 phage ply511 gene with a lysostaphin-encoding lss gene from S. simulans biovar
staphylolyticus in-frame with a Sep secretion signal. The resulting construct, Sep-6_His-Ply511, was
able to secrete both Ply511 and lysostaphin from Lactobacillus lactis, indicating that this recombinant
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organism could be used for industrial applications as a preservative to prevent contamination of foods
with Staphylococcus spp. and L. monocytogenes.
Staphylococcal food poisoning caused by heat stable enterotoxins produced by S. aureus is
frequently reported following the consumption of contaminated food and milk products [118].
Chang et al. [119] tested LysSA11, a S. aureus phage SA11-derived endolysin, to determine its
bactericidal activity in food and on food utensils artificially contaminated with MRSA. Treatment
of artificially contaminated ham and pasteurized milk with endolysin for 15 min resulted in 3.1
log10 CFU·cm−3 and 1.4 log10 CFU·ml−1 reductions in viable MRSA, respectively, at refrigeration
temperature (4 ◦C), and 3.4 log10 CFU·cm−3 and 2.0 log10 CFU·ml−1 reductions, respectively, at
room temperature (25 ◦C). The same group [120] tested the antibacterial potential of LysSA97 in
combination with several active compounds derived from essential oils used by the food industry
against S. aureus. They reported the superior activity of carvacrol in combination with LysSA97,
compared with that of the endolysin alone, in food products including beef and milk contaminated
with S. aureus. When used alone, LysSA97 and carvacrol reduced S. aureus concentrations by 0.8 and
1.0 log10 CFU·ml−1, respectively; however, a synergistic reduction of 4.5 log10 CFU·ml−1 was observed
when the treatments were combined. Similarly, Obeso et al. [121] and Rodriguez-Rubio et al. [122]
demonstrated the potential of phage-derived endolysins LysH5 and HydH5 (a hydrolase), respectively,
to protect milk products from S. aureus contamination.
Salmonella species are the leading cause of bacterial foodborne illness in the USA and many other
countries [123]. Salmonella disease outbreaks are associated with a wide variety of food products,
including red meats, poultry, and produce [124]. Several recombinant endolysins derived from
Salmonella phages have been characterized [125–127]. Interestingly, many of these endolysins have
activity outside of the host species of the parental phage, particularly when cell membrane-disrupting
chemicals are used in conjunction with the enzymes. Lim et al. [125] expressed the endolysins
and spanin proteins from Salmonella phage SPN1S and observed activity against both Salmonella
Typhimurium and E. coli isolates in buffer containing EDTA to destabilize the cell membranes.
Furthermore, some activity was also noted against typhoidal salmonellae, Shigella, Cronobacter,
Pseudomonas, and Vibrio species. Oliveira et al. [126] characterized a thermostable Salmonella endolysin,
Lys68, that displayed better activity at neutral pH and a wide temperature tolerance, maintaining
76.7% of its activity after 2 months at 4◦C and partial activity following exposure to 100 ◦C for 30 min.
Thermostability is a useful feature for diverse application, such as in heat treatment of food When
Lys68 was tested in combination with citric or malic acid against S. Typhimurium LT2, up to 5 log10
CFU reductions were achieved, with cells in stationary phase or in biofilms also reduced by up to
1 log10 CFU [126]. More recently, Rodriguez-Rubio et al. [127] reported a Salmonella phage endolysin,
Gp110, that possessed both a novel enzyme structure and N-acetylmuramidase lysis domain, and had
unusually high in vitro activity against Salmonella and other Gram-negative pathogens [127].
Around the turn of the century, a rare but frequently fatal disease of neonatal infants was first
reported to be associated with contamination of powdered infant milk formula with Enterobacter (now
Cronobacter) sakazakii [128]. It is now known that several species of Cronobacter can cause a variety
of diseases, including sepsis and severe meningitis, in neonates, as well as respiratory and urinary
tract infections in elderly and immunocompromised individuals. These opportunistic pathogens
are now under much scrutiny because of their ability to survive heat, desiccation, and acid stress,
which poses a risk of contamination of various milk powders, herbal teas, and other dried products
(https://www.cdc.gov/cronobacter/technical.html). Enderson et al. [129,130] expressed and purified
a peptidoglycan hydrolase (LysCs4) from C. sakazakii that had the highest sequence similarity to a
putative lysozyme from the temperate Cronobacter phage ES2. The purified lysozyme could degrade
the peptidoglycan from both Gram-negative and Gram-positive bacteria belonging to six different
genera, and could lyse outer membrane-permeabilized C. sakazakii. Similarly, the previously discussed
endolysins SPN1S [125] and Lys68 [126] are active against permeabilized C. sakazakii cells.
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Several groups have investigated the potential of endolysins active against B. cereus as biocides
and preservatives for use in the food industry [131–133]. B. cereus, a Gram-positive spore-forming
bacterium, is known for its ability to cause food poisoning by producing both an emetic toxin and
a diarrheal toxin [131]. Loessner et al. [132] isolated and characterized three endolysins (PlyBa,
Ply12, and Ply21) from the B. cereus phages Bastille, TP21, and 12826, respectively, and tested their
efficacy against a range of Gram-positive and Gram-negative bacteria. They reported that all three
endolysins were effective against 24 strains of B. cereus, along with several strains of B. thuringiensis.
Ply12 and Ply21 were found to be N-acetylmuramoyl-L-alanine amidases, while PlyBa could not be
classified at the time, but is also likely to be an amidase (http://www.uniprot.org/uniprot/P89927).
Park et al. [133] isolated a putative endolysin gene from the genome of B. cereus phage BPS13,
and expressed it in E. coli. The purified LysBPS13 protein, an amidase, retained its lytic activity
against B. cereus ATCC 10876 even after incubation at 100 ◦C for 30 min, demonstrating its
potential as a decontaminant in food processing applications. In contrast, Son et al. [131] proposed
L-alanoyl-D-glutamate endopeptidase LysB4 as a potential biocontrol agent against B. cereus and other
pathogenic bacteria. They confirmed the endopeptidase had a broad range of bactericidal activity
against Gram-positive bacteria, including B. cereus, B. subtilis, and L. monocytogenes, and also a few
Gram-negative bacteria. The endolysin showed optimum lytic activity at pH 8–10 and at 50 ◦C, making
it a suitable candidate for use in the food industry.
In addition to causing diseases in poultry, clostridial species are linked to food spoilage. In the
dairy industry, germinated Clostridium sporogenes and Clostridium tyrobutyricum can contribute to the
production of gases and acids that change the structural and sensory qualities of cheeses [134]. Mayer
et al. [135] isolated an N-acetylmuramoyl-L-alanine amidase, CS74L, from C. sporogenes and reported
that the purified protein effectively lysed C. sporogenes cells when added exogenously. Using the
turbidity assay and fresh bacterial cells, the authors also demonstrated that CS74L was active against
C. tyrobutyricum and Clostridium acetobutylicum, making it a candidate biopreservative for use in cheese.
The same group also characterized another endolysin isolated from a virulent phage, CPT1l, but this
enzyme had a more limited host range [134].
The dairy industry has a long-held interest in utilizing endolysins to control the cheese maturation
process. Vasala et al. [136] isolated a muramidase, Mur, from the LL-H phage of Lactobacillus delbrueckii
subsp. lactis that had activity against cell wall preparations of L. delbrueckii subsp. lactis, L. delbrueckii
subsp. bulgaricus, Lactobacillus acidophilus, Lactobacillus helveticus, and Pediococcus damnosus. Similarly,
Deutsch et al. [137] purified endolysin Mur-LH from a phage infecting the Swiss cheese starter
L. helveticus. This muramidase had activity against other lactobacilli, Leuconostoc lactis, P. acidilactici,
and, surprisingly, against B. subtilis. Kashige et al. [138] isolated an N-acetylmuramoyl-L-alanine
amidase from phage PL-1, which was originally isolated from an abnormal fermentation of a lactic
acid beverage produced using a Lactobacillus casei strain. There are also many examples of endolysins
isolated from lactococci, including from phages P001, C2 US3, and TUC2009 [136]. A survey of 18
L. lactis phage endolysins revealed that muramidases and amidases predominate [139].
In addition to the aforementioned enzymes, several other endolysins with potential to be used
against a range of foodborne microorganisms in different food types have been identified, and selected
examples of these are illustrated in Table 2.
Table 2. Examples of other potential uses of endolysins in foods.
Food Organism Endolysin Reference
Fish Shewanella putrefaciens ORF62 Han et al. [140]
Vegetable fermentation Leuconostoc mesenteroides ORF35 Lu et al. [141]
Kimchi Lactobacillus plantarum SC921 lysin Yoon et al. [142]




Escherichia coli O157:H7, Shigella flexneri
λ lysozyme
(with high pressure treatment) Nakimbugwe et al. [144]
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Table 2. Cont.
Food Organism Endolysin Reference
Shellfish Vibrio parahaemolyticus Lysqdvp001 Wang et al. [145]
Lettuce Listeria innocua Ply500(with packaging film) Solanki et al. [146]
Milk Listeria monocytogenes PlyP825(with high pressure treatment) Misiou et al. [147]
Mozzarella cheese L. monocytogenes PlyP825(with high pressure treatment) Misiou et al. [147]
The growth of biofilms in food processing environments leads to an increased risk of microbial
contamination of foods [148]. There are some examples of endolysins being used to disrupt biofilms
with relevance to the food industry. Gutierrez et al. [149] investigated the activity of three endolysins
(LysH5, CHAP-SH3b, and HydH5-SH3b) against biofilms formed by two S. aureus isolates from
food. Preformed biofilms were treated with 7 µM of the enzymes, with LysH5 and CHAP-SH3b most
effective against strains IPLA1 and Sa9, respectively. In another study, an N-acetylmuramoyl-L-alanine
amidase was used to disrupt Listeria biofilms in vitro, but was found to be most effective when
used in combination with a protease [150]. The Salmonella-phage endolysin Lys68 also reduced the
concentration of cells in a S. Typhimurium LT2 biofilm by up to 1.2 log10 CFU [128], but this required
the presence of either citric or maleic acid to permeabilize the cell membranes.
Phytopathogenic bacteria have a significant global economic cost, and are the cause of multiple
food security issues [151]. The use of antibiotics in plant agriculture is controversial because its
contribution to the development of antibiotic resistance in human pathogens is undetermined [152]
Although its impact may be small, ideally, an alternative strategy to control phytopathogenic bacteria
will be developed. As such, the use of endolysins to protect plants from bacterial diseases has
been proposed [16]. Widespread implementation of these endolysins will, however, be a significant
challenge because of the vast number of crops that would require treatment, and the presence of
beneficial soil-borne bacteria. A proposed strategy is the development of transgenic crops that express
endolysins, providing protection against the pathogenic bacteria. The potential of this approach
has been demonstrated by Düring et al. [153], who produced transgenic potato plants expressing
T4 lysozyme. These engineered plants displayed resistance to Pectobacterium carotovora (formerly
Erwinia carotovora) species, which are the cause soft rot [153,154]. Wittmann et al. [155] produced
transgenic tomato plants expressing the endolysins from bacteriophage CMP1 in an attempt to prevent
Clavibacter michiganensis subsp. michiganensis infection, the causative agent of bacterial wilt and
canker [156]. No symptoms of bacterial infection were observed in the transgenic plants; however,
the bacteria were not completely eliminated [155]. A key limitation of this research was that the
bacterial infection model may not be representative of natural infection, and therefore the efficacy
of these transgenic tomato plants should to be evaluated under more natural conditions. It is also
unknown whether C. michiganensis subsp. michiganensis could acquire resistance to these transgenic
plants. However, this is a promising advancement in the development of transgenic plants. As new
endolysins are characterized, more opportunities for bioengineering to optimize the activity of the
protection mechanism will be possible.
Xanthmonas oryzae pv. oryzae causes bacterial leaf blight in rice [157], with a number of antibiotic
resistant strains having been isolated [158]. In 2006, Lee et al. [159] identified Lys411 from ΦXo411,
which exhibited strong lytic activity against Xanthmonas. Additionally, it displayed activity against
the multidrug-resistant bacterium Stenotrophomonas maltophilia [159], which has growing clinical
significance with regards to nosocomial infections and immunocompromised patients [160]. However,
no follow-up studies investigating Lys411 have been published, which means the potential of this
enzyme for medical or agriculture applications is unknown.
Attai et al. [161] recently characterized an endolysin from bacteriophages Atu_ph02 and Atu_ph03
for the biocontrol of Agrobacterium tumefaciens. A. tumefaciens is a Gram-negative soil-borne bacterium
that is the etiologic agent of crown gall disease in a variety of orchard and vineyard crops [162].
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Its severity and widespread impact has contributed to it to becoming the subject of many recent
studies [163]. The lytic protein displayed interesting properties, with the ability to not only rapidly
lyse the cell, but to also block cell division, ensuring potent antimicrobial activity [161]. Therefore,
the enzyme is a candidate for biocontrol of A. tumefaciens; however, the method of implementation
needs to be researched before a viable strategy for crop protection can be developed. The practicalities
of implementing these endolysins on a global scale for individual phytobacteria may be a significant
challenge, and may contribute to the limited information currently available on the use of endolysins
for treatment of plant bacterial diseases. However, the cost to society of plant bacterial disease as
current strategies become ineffective means that endolysin research should be an important focus.
5. Challenges of Endolysin Development and Engineering
The potential for endolysins to supplement, or replace antibiotics is exciting. However, this field
is still emerging, with very few clinical trials on endolysin-based drugs being conducted. There are
a number of challenges and considerations which researchers still face to bring these to market.
As highlighted by several studies, the immunogenicity of endolysins must be considered and fully
assessed. Undesirable immune responses to these foreign proteins could result in decreased efficacy of
the enzymes, or possibly anaphylaxis and autoimmunity [164,165]. While there are studies that have
reported on the immunogenicity in the application of endolysins [40–42,45,60,63] assessing the degree
of immunogenicity in humans using traditional animal models has so far proven unreliable [166].
This was highlighted in studies of SAL200, which showed varying degrees of antibody production
between rats, dogs, monkeys and humans [40–42]. Although the efficacy of the endolysin may not be
observably impacted in vitro or in vivo, the clinical effects may be more significant. Until more human
and animal-specific (for animal husbandry applications) clinical trials are conducted, the immunogenic
nature of endolysins will remain unpredicatable.
In light of the current antibiotic resistance crisis, new antibacterials should be rigorously assessed
for their potential susceptibility to developed resistance by bacteria. Promisingly, bacterial mutants
resistant to endolysins are very infrequent [28–30,167]. Fischetti [167] proposed the lack of developed
resistance to endolysins has resulted from the evolution of the interactions between bacteriophage and
bacteria. The endolysins have evolved to target essential, immutable, molecules within the cell wall,
thereby reducing the likelihood of the bacteria developing resistance mechanisms [167]. However,
there are also reports of resistance to other peptidoglycan-cleaving enzymes including lysozymes and
lysostaphin [168–173]. In the event of bacterial adaptation, enzyme engineering may prove useful to
combat changes to bacteria in order to maintain the efficacy of endolysins.
The potential for endolysin bioengineering are seemingly endless, including optimizing or
changing the catalytic abilities, modifying the lytic spectrum, improving its ability to permeate outer
membranes and increasing stability (Table 1). Designing new enzymes requires an understanding of
the structure and function of individual domains, the interactions between domains, the placement and
composition of linker regions, and elucidation of key residues involved in catalysis. Bioinformatics and
structural characterization studies are integral in this process [174]. Often, structural characterization
can be achieved by X-ray crystallography, a powerful and effective technique for elucidating high
resolution 3-D structures of proteins [11]; however, the limited ability to crystallize endolysins is
a major challenge. The majority of endolysin crystal structures published to date are of single
domains, with very few full-length endolysin crystal structures having been solved. This is
attributed to the short flexible linker regions between domains [8], as protein flexibility is a common
hindrance of crystal formation [175]. It is important to study full-length proteins to get a better
understanding of the potential synergistic/antagonistic interactions between domains. Because of
the difficulties in obtaining endolysin crystals, alternative structural characterization strategies need
to be considered. These include the fusion of endolysins to proteins to decrease their flexibility,
thereby allowing for crystallography, and other structural elucidation techniques such as nuclear
magnetic resonance [176,177] and cryo-electron microscopy [178]. Although these approaches also
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have limitations, such as physiological relevance or size restrictions, exploration of these techniques
may advance the structural characterization of endolysins.
6. Conclusions
The field of endolysin research is dynamic, with many potential applications being investigated
in the medical, veterinary, and food sectors. The current global crisis of antimicrobial resistance
is driving much of this work, with endolysins showing great promise to replace or supplement
antibiotics. Engineering endolysins with optimized or new properties provides an opportunity to
create even more effective tools. As more bacteriophage endolysins are biochemically and structurally
characterized, the ability to design new enzymes improves, therefore expanding the arsenal of lytic
tools. However, there are still many challenges that need to be addressed before this technology can be
widely adopted by practitioners and industry. While many researchers have described the isolation
and in vitro characterization of endolysins, establishing the in vivo efficacy and operating parameters
of endolysins for human clinical use, food protection and supplementation, animal husbandry and
welfare, and in the environment will be of great importance over the coming years. New technology to
cost-effectively scale up endolysin production is also required, as this is currently a significant barrier
to implementation. Finally, regulatory pathways need to be established for the use of endolysins in
each of the various fields of application, and this can only be achieved by early and effective dialogue
with the relevant authorities.
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